Credit Suisse’s Adicet Bio ACET Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-835
Closed -$76.9K 3161
2023
Q1
$76.9K Hold
835
﹤0.01% 3222
2022
Q4
$119K Sell
835
-43
-5% -$10.7K ﹤0.01% 3301
2022
Q3
$200K Buy
878
+9
+1% +$2.28K ﹤0.01% 3243
2022
Q2
$203K Buy
+869
New +$191K ﹤0.01% 3321

Other funds holding ACET

Credit Suisse's ACET Position: Q2 2023 in Review

Credit Suisse sold out of Adicet Bio (ACET) in Q2 2023, closing a stake of 835 shares — an estimated $76.9K sold.

Credit Suisse first reported a position in ACET in Q2 2022 and held it in 4 quarters. The position peaked at $203K in Q2 2022. 94 funds tracked by Wall St. Rank hold ACET as of Q2 2023.

  • Credit Suisse reported no remaining Adicet Bio position as of Q2 2023 after selling out during the quarter.
  • Credit Suisse sold 835 Adicet Bio shares in Q2 2023, an estimated $76.9K.
  • Credit Suisse first reported a position in Adicet Bio in Q2 2022 and held it in 4 quarters.
  • Credit Suisse's Adicet Bio position peaked at $203K in Q2 2022.
  • 94 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.